Hou Wanting, Yang Biao, Zhu Hong
Department of Medical Oncology Cancer Center, West China Hospital, Sichuan University, Chengdu 610017, China.
Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu 610017, China.
Pharmaceutics. 2022 Sep 24;14(10):2033. doi: 10.3390/pharmaceutics14102033.
Immunotherapy has dramatically changed prognosis for patients with malignant tumors. However, as a non-immunogenic tumor, pancreatic ductal adenocarcinoma (PDAC) has a low response to immunotherapy. Factors that contribute to the inefficiency of PDAC immunotherapy include the tumor microenvironment (TME) and its dense stroma, which acts as a barrier for drug delivery and immune cell infiltration. Recent studies have shown that nanoparticle-based therapeutic strategies have more promising applications in improving drug delivery and reversing the immunosuppressive TME for PDAC. Therefore, nanomaterial-based therapeutic approaches are expected to enhance the effectiveness of immunotherapy and improve prognosis of patients with PDAC. Here, we outline the status and dilemma of PDAC immunotherapy, and summarize the latest advances in nanoparticle-based treatment strategies to enhance the efficacy of PDAC immunotherapy.
免疫疗法极大地改变了恶性肿瘤患者的预后。然而，作为一种非免疫原性肿瘤，胰腺导管腺癌（PDAC）对免疫疗法的反应较低。导致PDAC免疫疗法效率低下的因素包括肿瘤微环境（TME）及其致密的基质，后者充当了药物递送和免疫细胞浸润的屏障。最近的研究表明，基于纳米颗粒的治疗策略在改善PDAC的药物递送和逆转免疫抑制性TME方面具有更广阔的应用前景。因此，基于纳米材料的治疗方法有望提高免疫疗法的有效性并改善PDAC患者的预后。在此，我们概述了PDAC免疫疗法的现状和困境，并总结了基于纳米颗粒的治疗策略在提高PDAC免疫疗法疗效方面的最新进展。
